United States: How FDA Differs From CMS In Clinical Lab Test Oversight

Law360, New York (March 14, 2013, 12:36 PM ET) - The U.S. Food and Drug Administration has previously announced an interest in regulating diagnostic tests used in providing personalized medicine clinical care. Interested stakeholders such as the American Clinical Laboratory Association, the College of American Pathologists and the Association for Molecular Pathology, have weighed in on whether the FDA can and should expand its jurisdiction to laboratory-developed tests (LDTs) performed by clinical laboratories.

To the end of understanding the issues and concerns of stakeholders and the public, the Personalized Medicine Coalition (PMC) recently issued a white paper reporting on the regulatory landscape for personalized medicine tests and services in U.S. clinical practice. The report "Personalized Medicine Regulation: Pathways for Oversight of Diagnostics" (available here) explains the current regulatory oversight of diagnostic tests and, in particular, LDTs, and contrasts their regulation with regulation of certain diagnostic tests by the FDA.

Current Regulatory Framework

Personalized medicine relies on the accurate analysis of a patient's clinical symptoms and/or genome. Diagnostic medicine is integral to the basic tenet of personalized medicine - finding the right treatment for the right patient at the right time. Thus, the safe and appropriate use of reliable and valid diagnostic tests is central to the successful adoption of personalized medicine.

The report notes that two separate agencies in the U.S. Department of Health and Human Services oversee personalized medicine products and services in the United States. The FDA regulates pharmaceutical products, biological products and medical devices used in patient care, including care that is considered personalized medicine.

Clinical laboratories that perform diagnostic medicine such as genetic analysis (typically called LDTs) are under the jurisdiction of the Centers for Medicare and Medicaid Services, pursuant to the Clinical Laboratory Improvement Amendments (CLIA). CMS certification currently is required before clinical laboratories can generally perform diagnostic tests and interpret and report results to health care providers.

Comparison of FDA and CMS Regulation of Diagnostic Tests

The PMC report reviews in detail the structure of the FDA and the CMS and the current oversight of LDTs by each agency. The PMC report notes five key ways the FDA's approach to regulating the manufacture and distribution of diagnostic medical devices differs from the CMS' approach to regulating diagnostic test services performed by laboratories:

Requirements for Evidence of Analytical and Clinical Validity

The PMC report notes that the FDA regulated tests (termed "in vitro diagnostics" or "IVDs") require clinical evidence to support the intended use and indications for the test (i.e., the test's ability to identify or predict the disorder of interest) and require review of analytical performance.

CLIA regulations for LDTs require a demonstration of laboratory performance and that the test methodologies selected have the capability of providing quality results. However, this information generally does not require review by an external body prior to the lab offering the test unless required by state law.

Time to Market

Because the FDA requires detailed clinical review of IVDs prior to market, the premarket review process for tests regulated by the FDA can take several months to years. The FDA can also require approval or clearance of new premarket submissions if changes are made to diagnostic tests after FDA approval or clearance. Laboratories using FDA-approved tests must also comply with CLIA quality controls. In contrast, LDTs do not require review or approval from an outside body prior to clinical use, again unless required by state law.

Labeling and Promotion

The FDA permits the promotion of regulated IVDs only in accordance with their cleared or approved intended uses. The CMS, in contrast, does not restrict the clinical claims for LDTs developed by CLIA labs. However, advertisement of clinical claims for LDTs is subject to oversight by a separate federal agency - the Federal Trade Commission and applicable state laws - and must carry a disclaimer that the test has not been cleared or approved by the FDA.

Quality Programs and Post-Market Capabilities

The quality programs for FDA-regulated IVDs and LDTs have different elements that may or may not overlap. In brief, FDA-regulated tests must utilized design controls for development and validation of diagnostic assays and other process controls, which are not required for LDTs.

LDTs, in contrast, need only to follow good laboratory practice standards and process requirements. Also, manufacturers of IVDs are subject to periodic FDA inspection while CLIA laboratories generally are subject only to their own quality control inspections for compliance with CLIA regulations.

FDA regulations also require reporting of adverse events associated with a product, and the manufacturer must have a process for implementing a product recall. CLIA regulations, in contrast, simply require policies and procedures to monitor, access and correct problems uncovered during use of the tests.

Financial Consequences

CLIA laboratories pay a user fee for initial laboratory certification and biennial recertification based on the volume of clinical testing. Manufacturers of IVDs pay fees for diagnostic premarket submissions and pay an annual establishment registration fee.

As of Jan. 1, of 2013, FDA-regulated tests (with a few exceptions) are subject to a 2.3-percent federal excise tax pursuant to the Patient Protection and Affordable Care Act. If LDTs were to be regulated by the FDA, LDTs would likely be subject to the FDA fees and excise tax in addition to CLIA fees.

Recommendations and Conclusion

The PMC report indicates that there are significant differences of opinion among stakeholders on the optimal level of regulation and oversight of LDTs, especially when the outcome of an LDT impacts pharmacological intervention. Some stakeholders view FDA regulation of LDTs, in addition to CMS regulation, as creating a disproportionate burden on laboratories that would slow innovation to the detriment of physicians and patients and would unnecessarily increase the cost of providing laboratory services.

Other stakeholders opine that the current regulatory oversight of LDTs is insufficient in view of the increased complexity of the tests. They argue that a risk-based FDA approach can sustain and promote innovation, while benefiting patient safety.

The PMC report closes by noting, "[w]hether the various stakeholders working with Congress, the interested government agencies, and other authoritative bodies can reach an understanding on the optimal path forward remains to be seen."

Those institutions or individuals involved in LDTs would be well advised to closely monitor ongoing discussions of this topic in the coming months and provide their feedback during the public comment period for any proposed regulations governing LDTs.

Previously published by Law360

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions